Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Aug 13, 2021 (5 years ago)

Chantix (varenicline) (Varenicline Tartrate)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

Cause type: Nitrosamine impurity

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls. All nitrosamine impurity recalls.

What was recalled

Chantix (varenicline) tablets 1 mg, 56 Tablets, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Ireland, NDC 0069-0469-56.

Affected NDC 0069-0469-56

Compare with the code on your package — it is the most precise check available.

Drug: Varenicline

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Chantix
varenicline tartrate
NDC 00069-0469
1 mg/1 Tablet, Film Coated
Oral
Pfizer Laboratories Div Pfizer Inc Rx
Recalling firm
Pfizer Inc.
NDC code
0069-0469-56
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0810-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Varenicline recalls

See all
Class III · Low risk

Varenicline Tablets

Sub potent drug: during the 9-month stability test conducted, the assay value for the affected lot was below specification limit.

Ongoing Wrong potency / content Dr. Reddy's Laboratories, Inc. NDC 43598-908-56 D-0219-2026
Class II · Moderate risk

Chantix (varenicline)

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

Ongoing Nitrosamine impurity Pfizer Inc. NDC 0069-0469-03 D-0811-2021
Class II · Moderate risk

Chantix (varenicline)

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

Ongoing Nitrosamine impurity Pfizer Inc. NDC 0069-0468-56 D-0809-2021
Class II · Moderate risk

Chantix (varenicline)

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit

Ongoing Nitrosamine impurity Pfizer Inc. NDC 00069-0471-03 D-0808-2021
Class II · Moderate risk

Chantix (varenicline)

CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit

Ongoing Nitrosamine impurity Pfizer Inc. NDC 0069-0469-56 D-0701-2021

Other recalls by Pfizer Inc.

All 2021 recalls